Investor FAQ

1.On which exchange is Verastem Oncology™ listed and what is the ticker symbol and when did it go public?
 Verastem Oncology is traded on the NASDAQ global market under the symbol VSTM, and its CUSIP number is 92337C 104. Verastem’s initial public offering (IPO) occurred on January 27, 2012

2.Where is Verastem Oncology incorporated?
 Verastem Oncology is incorporated in the state of Delaware.

3.Where is Verastem Oncology headquartered?
 Verastem Oncology is headquartered at 117 Kendrick Street, Suite 500, Needham, MA 02494, U.S. The main phone number is 781-292-4200.

4.Do you pay dividends or is there a reimbursement plan?
 Verastem Oncology does not currently offer a dividend or stock reimbursement plan

5.Who is Verastem Oncology’s transfer agent?
 Computershare Trust Company, N.A.
P.O. Box 43078
Providence, RI 02940
www.computershare.com
1-800-962-4284 (from the US, Canada, Puerto Rico)
1-781-575-3120 (non-US)

6.If my address changes, whom should I notify?
 You must send both your old and new address to our transfer agent, Computershare Trust Company, N.A., by U.S. mail. Each stockholder in question must sign the request for an address change.

7.What is Verastem Oncology’s fiscal year-end?
 December 31.

8.Who are Verastem Oncology’s independent auditors?
 Ernst & Young LLP
200 Clarendon Street
Boston, MA 02116
617-266-2000

9.Who is Verastem Oncology’s legal counsel?
 Ropes & Gray
Prudential Tower
800 Boylston Street
Boston, MA 02199-3600
T +1 617 951 7000

10.Who should I contact if I have further questions?
 Verastem Oncology's investor relations department is happy to answer any shareholder questions. You may contact Verastem Oncology's investor relations by phone at 781-292-4200, or by email at info@verastem.com